Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctiontranscription corepressor activity

DDIT3 ZMYND8

1.91e-0322962GO:0003714
GeneOntologyMolecularFunctionDNA-binding transcription activator activity, RNA polymerase II-specific

DMRT1 DDIT3

1.09e-0256062GO:0001228
GeneOntologyMolecularFunctiontranscription coregulator activity

DDIT3 ZMYND8

1.10e-0256262GO:0003712
GeneOntologyMolecularFunctionDNA-binding transcription activator activity

DMRT1 DDIT3

1.12e-0256662GO:0001216
GeneOntologyMolecularFunctionDNA-binding transcription factor binding

DDIT3 ZMYND8

1.18e-0258262GO:0140297
GeneOntologyBiologicalProcessregulation of protein localization to membrane

TCAF1 ZMYND8

1.91e-0323762GO:1905475
GeneOntologyBiologicalProcessnegative regulation of transcription by RNA polymerase II

DMRT1 DDIT3 ZMYND8

2.36e-03105363GO:0000122
GeneOntologyBiologicalProcesspositive regulation of transcription by RNA polymerase II

DMRT1 DDIT3 ZMYND8

5.23e-03139063GO:0045944
GeneOntologyBiologicalProcessnegative regulation of DNA-templated transcription

DMRT1 DDIT3 ZMYND8

5.33e-03139963GO:0045892
GeneOntologyBiologicalProcessnegative regulation of RNA biosynthetic process

DMRT1 DDIT3 ZMYND8

5.48e-03141363GO:1902679
GeneOntologyCellularComponentchromatin

DMRT1 DDIT3 ZMYND8

6.02e-03148063GO:0000785
CoexpressionPHONG_TNF_RESPONSE_VIA_P38_COMPLETE

DDIT3 TCAF1 ZMYND8

1.21e-0522463M2500
CoexpressionDELASERNA_MYOD_TARGETS_DN

DDIT3 ZMYND8

6.69e-055662M1541
CoexpressionDELASERNA_MYOD_TARGETS_DN

DDIT3 ZMYND8

7.43e-055962MM659
CoexpressionTIEN_INTESTINE_PROBIOTICS_2HR_DN

TCAF1 ZMYND8

1.69e-048962M8916
CoexpressionWAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D

DDIT3 TCAF1 ZMYND8

6.65e-0486563M2417
CoexpressionWAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D

DDIT3 TCAF1 ZMYND8

7.18e-0488863MM1315
CoexpressionGSE3982_DC_VS_BASOPHIL_DN

DDIT3 ZMYND8

8.43e-0419962M5473
CoexpressionGSE27786_LSK_VS_CD8_TCELL_UP

TCAF1 ZMYND8

8.43e-0419962M4749
CoexpressionGSE27786_CD4_TCELL_VS_NKCELL_UP

TCAF1 ZMYND8

8.52e-0420062M4822
CoexpressionGSE40184_HEALTHY_VS_HCV_INFECTED_DONOR_PBMC_DN

DMRT1 ZMYND8

8.52e-0420062M9404
CoexpressionGSE43955_TH0_VS_TGFB_IL6_TH17_ACT_CD4_TCELL_52H_UP

DMRT1 DDIT3

8.52e-0420062M9633
CoexpressionGSE360_DC_VS_MAC_M_TUBERCULOSIS_DN

TCAF1 ZMYND8

8.52e-0420062M5191
CoexpressionGSE22432_PDC_VS_TGFB1_TREATEDCOMMON_DC_PROGENITOR_DN

DDIT3 ZMYND8

8.52e-0420062M7833
CoexpressionAMUNDSON_RESPONSE_TO_ARSENITE

DDIT3 ZMYND8

1.02e-0321962M262
ToppCellCOVID-19_Mild-Neu_1|World / 5 Neutrophil clusters in COVID-19 patients

DMRT1 ANKFN1

1.14e-0412562e58c208b4355252ceabe04a468dd19a1f436182c
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Degenerative_Proximal_Tubule_Epithelial_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

DMRT1 ANKFN1

2.03e-04167623edb0570e583bb527165bcd8a4c25a042054043b
ToppCell3'-Distal_airway-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ANKFN1 CPXCR1

2.44e-041836258847e8f3a7ce3e33adba9477bcd55e769a64a90
ToppCellBrain_organoid-organoid_Tanaka_cellReport-1m-Mesenchymal-Mesoderm|1m / Sample Type, Dataset, Time_group, and Cell type.

DDIT3 ANKFN1

2.91e-0420062c0ad32e9dd7f481c2665587fd8bd9fffc2e725f9
DrugNorcyclobenzaprine [303-50-4]; Up 200; 15.4uM; PC3; HT_HG-U133A

DMRT1 DDIT3 ZMYND8

1.14e-05191634190_UP
DrugDemecolcine

DMRT1 DDIT3 TCAF1 ZMYND8

3.10e-0587864ctd:D003703
DrugMG-262; Up 200; 0.1uM; PC3; HT_HG-U133A

DMRT1 DDIT3

7.32e-04161627068_UP
DrugMG-262; Up 200; 0.1uM; PC3; HT_HG-U133A

DMRT1 DDIT3

7.59e-04164627079_UP
Druggeldanamycin; Up 200; 1uM; MCF7; HT_HG-U133A_EA

DDIT3 ZMYND8

7.77e-04166621066_UP
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A_EA

DDIT3 ZMYND8

8.06e-04169621056_UP
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A_EA

DDIT3 ZMYND8

8.54e-04174621044_UP
Drug14-deoxy-11,12-didehydroandrographolide

DDIT3 TCAF1

8.63e-0417562ctd:C495626
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A_EA

DDIT3 ZMYND8

8.93e-0417862916_UP
DrugTriamterene [396-01-0]; Up 200; 15.8uM; PC3; HT_HG-U133A

DDIT3 ZMYND8

9.03e-04179621819_UP
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A_EA

DDIT3 ZMYND8

9.13e-0418062947_UP
DrugThioridazine hydrochloride [130-61-0]; Up 200; 9.8uM; PC3; HG-U133A

DDIT3 ZMYND8

9.33e-04182621905_UP
DrugGossypol [303-45-7]; Up 200; 7.8uM; PC3; HT_HG-U133A

DDIT3 ZMYND8

9.33e-04182623740_UP
DrugSTOCK1N-35215; Up 200; 10uM; PC3; HT_HG-U133A

DDIT3 ZMYND8

9.33e-04182626427_UP
DrugUrsolic acid [77-52-1]; Up 200; 8.8uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

9.33e-04182622230_UP
DrugZuclopenthixol hydrochloride [633-59-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

9.44e-04183624843_UP
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

9.44e-04183626944_UP
Drugprochlorperazine dimaleate salt; Up 200; 10uM; PC3; HT_HG-U133A

DMRT1 DDIT3

9.54e-04184624439_UP
DrugDisulfiram [97-77-8]; Up 200; 13.4uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

9.64e-04185622215_UP
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A_EA

DDIT3 ZMYND8

9.64e-0418562831_UP
DrugMifepristone [84371-65-3]; Up 200; 9.4uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

9.85e-04187627183_UP
DrugPhenacetin [62-44-2]; Up 200; 22.4uM; MCF7; HT_HG-U133A

DMRT1 ZMYND8

1.01e-03189622832_UP
DrugSecurinine [5610-40-2]; Up 200; 18.4uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.04e-03192623470_UP
DrugClotrimazole [23593-75-1]; Up 200; 11.6uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.05e-03193626207_UP
DrugProbenecid [57-66-9]; Up 200; 14uM; MCF7; HT_HG-U133A

DMRT1 ZMYND8

1.06e-03194622825_UP
DrugSkimmianine [83-95-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.06e-03194626242_UP
DrugAvermectin B1 [71751-41-2]; Up 200; 4.8uM; MCF7; HT_HG-U133A

DMRT1 DDIT3

1.06e-03194626081_UP
DrugVerteporfin [129497-78-5]; Up 200; 2.8uM; MCF7; HT_HG-U133A

DMRT1 DDIT3

1.06e-03194623556_UP
DrugAmiodarone hydrochloride [19774-82-4]; Up 200; 5.8uM; PC3; HT_HG-U133A

DMRT1 DDIT3

1.07e-03195624657_UP
DrugDihydroergocristine mesylate [24730-10-7]; Up 200; 5.6uM; MCF7; HT_HG-U133A

DMRT1 ZMYND8

1.07e-03195622895_UP
DrugLuteolin [491-70-3]; Down 200; 14uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.07e-03195625004_DN
Drug(-)-Eseroline fumarate salt [104015-29-4]; Up 200; 12uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.08e-03196623530_UP
DrugPiretanide [55837-27-9]; Down 200; 11uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.08e-03196623567_DN
DrugHymecromone [90-33-5]; Down 200; 22.8uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.08e-03196623383_DN
DrugSTOCK1N-35215; Up 200; 10uM; PC3; HT_HG-U133A

DMRT1 DDIT3

1.08e-03196626380_UP
DrugDequalinium dichloride [522-51-0]; Up 200; 7.6uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.08e-03196622631_UP
DrugTimolol maleate salt [26921-17-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.08e-03196626483_DN
DrugPancuronium bromide [15500-66-0]; Down 200; 5.4uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.08e-03196627329_DN
Drughaloperidol; Up 200; 10uM; PC3; HT_HG-U133A

DDIT3 ZMYND8

1.09e-03197621244_UP
DrugDoxazosin mesylate [77883-43-3]; Down 200; 7.4uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.09e-03197624988_DN
DrugTrimeprazine tartrate [4330-99-8]; Up 200; 5.4uM; PC3; HT_HG-U133A

DMRT1 DDIT3

1.09e-03197625881_UP
DrugMedrysone [2668-66-8]; Up 200; 11.6uM; MCF7; HT_HG-U133A

DMRT1 DDIT3

1.09e-03197624727_UP
DrugDAPH; Up 200; 10uM; MCF7; HG-U133A

DDIT3 ZMYND8

1.09e-0319762624_UP
DrugCinoxacin [28657-80-9]; Down 200; 15.2uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.09e-03197626257_DN
DrugC75; Up 200; 10uM; MCF7; HT_HG-U133A

DMRT1 ZMYND8

1.09e-03197626423_UP
Drugvaldecoxib; Down 200; 10uM; PC3; HT_HG-U133A

DMRT1 ZMYND8

1.09e-03197626408_DN
DrugNeostigmine bromide [114-80-7]; Up 200; 13.2uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.09e-03197625335_UP
DrugRamipril [87333-19-5]; Down 200; 9.6uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.09e-03197626792_DN
DrugThiorphan [76721-89-6]; Down 200; 15.8uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.09e-03197622752_DN
DrugPhensuximide [86-34-0]; Up 200; 21.2uM; MCF7; HT_HG-U133A

DMRT1 DDIT3

1.10e-03198623521_UP
Drughaloperidol; Up 200; 10uM; PC3; HT_HG-U133A

DDIT3 ZMYND8

1.10e-03198621203_UP
DrugClorgyline hydrochloride [17780-75-5]; Up 200; 13uM; MCF7; HT_HG-U133A

DMRT1 DDIT3

1.10e-03198623219_UP
DrugTodralazine hydrochloride [3778-76-5]; Down 200; 14.8uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.10e-03198621677_DN
DrugCeftazidime pentahydrate [78439-06-2]; Up 200; 6.2uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.10e-03198625473_UP
DrugZoxazolamine [61-80-3]; Down 200; 23.8uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.10e-03198622625_DN
DrugTriamterene [396-01-0]; Up 200; 15.8uM; PC3; HT_HG-U133A

DDIT3 ZMYND8

1.10e-03198627307_UP
DrugFlucytosine [2022-85-7]; Up 200; 31uM; MCF7; HT_HG-U133A

DMRT1 ZMYND8

1.10e-03198625289_UP
DrugLevonordefrin [829-74-3]; Up 200; 21.8uM; MCF7; HT_HG-U133A

DMRT1 ZMYND8

1.10e-03198623450_UP
DrugIvermectin [70288-86-7]; Up 200; 4.6uM; PC3; HT_HG-U133A

DDIT3 ZMYND8

1.11e-03199625853_UP
DrugCinoxacin [28657-80-9]; Up 200; 15.2uM; PC3; HT_HG-U133A

DMRT1 ZMYND8

1.11e-03199625783_UP
DrugDiethylstilbestrol [56-53-1]; Up 200; 15uM; HL60; HT_HG-U133A

DMRT1 ZMYND8

1.11e-03199622567_UP
DrugMeptazinol hydrochloride [59263-76-2]; Up 200; 14.8uM; PC3; HT_HG-U133A

DMRT1 ZMYND8

1.11e-03199624188_UP
DrugCloxacillin sodium salt [642-78-4]; Down 200; 8.8uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.11e-03199622289_DN
DrugLisinopril [83915-83-7]; Down 200; 9uM; MCF7; HT_HG-U133A

DDIT3 ZMYND8

1.11e-03199627403_DN
Drug3-nitropropionic acid; Down 200; 10uM; PC3; HT_HG-U133A

DMRT1 ZMYND8

1.13e-03200626407_DN
Drugciglitazone

DDIT3 TCAF1

1.63e-0324162ctd:C039671
Diseasechronotype measurement

DMRT1 ANKFN1

1.24e-0288262EFO_0008328
Diseaseneuroimaging measurement

DMRT1 ANKFN1

1.78e-02106962EFO_0004346
Diseaseunipolar depression

DMRT1 ZMYND8

2.24e-02120662EFO_0003761

Protein segments in the cluster

PeptideGeneStartEntry
HTMNVMITNTNNGWK

CPXCR1

261

Q8N123
MLKMSGWQRQSQNQS

DDIT3

1

P0DPQ6
QTSSQKWHMQKMQRQ

ZMYND8

826

Q9ULU4
NQWQMKNMENRHAMS

DMRT1

271

Q9Y5R6
MNLWVKMFSHQVQKN

TCAF1

866

Q9Y4C2
WNCRVKMTQQMQNLH

ANKFN1

66

Q8N957